We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU
Read MoreHide Full Article
Key Takeaways
Amarin surged 27.3% after licensing Vazkepa to Recordati for commercialization across 59 EU countries.
The deal includes $25M upfront, up to $150M in milestones, and supply-based royalty revenues.
AMRN expects $70M in EU cost savings over 12 months as part of a broader strategy to fuel growth.
Shares of Amarin (AMRN - Free Report) jumped 27.3% on Tuesday after the company announced that it has signed an exclusive long-term license and supply agreement with Italy-based Recordati to commercialize its sole marketed drug, Vazkepa (icosapent ethyl), across 59 countries in the EU.
AMRN’s Vazkepa is currently approved in the EU as an adjunct to diet for treating severe hypertriglyceridemia or elevated triglyceride levels and to reduce the risk of cardiovascular events (CV) in patients with persistent elevated triglycerides on statin therapy for LDL-C. The drug is also approved in the United States for the same indications as in the EU, under the brand name Vascepa.
The agreement with Recordati builds on Vazkepa’s early success in the EU, where it enjoys patent protection up to 2039, and focuses on expanding the product’s reach to patients at risk of CV, thereby boosting sales. Additionally, it will also enable Amarin to cut operational costs, thereby enhancing its financial strength.
Financial Considerations for AMRN’s Licensing Deal With Recordati
The deal grants Recordati an exclusive license to market Amarin’s Vazkepa across Europe. In return, AMRN will receive an upfront payment of $25 million, along with potential milestone payments of up to $150 million, contingent on Recordati meeting certain predefined annual net sales targets. Amarin is also entitled to receive certain supply-based revenues, including royalties related to the product’s supply under the licensing agreement.
Year to date, shares of Amarin have rallied 65.3% against the industry’s decline of 4.2%.
Image Source: Zacks Investment Research
How the Recordati Deal Benefits AMRN’s Future Growth Strategy
The partnership with Recordati further strengthens Amarin’s cash position. The deal also supports Amarin’s transition toward a leaner operating model, projected to deliver approximately $70 million in cost savings over the next 12 months, primarily from reduced commercialization expenses in the EU. This restructuring strengthens Amarin’s financial position and accelerates its path to achieving positive cash flow, while creating new revenue opportunities through supply agreements and milestone payments. As of March-end, AMRN’s balance sheet reflects nearly $300 million in cash with no debt.
Vazkepa is a strong addition to Recordati’s established cardiovascular portfolio, which accounts for around 25% of its Specialty and Primary Care business and includes treatments for conditions such as hypertension and heart failure. With operations in more than 150 countries, including a solid presence across the EU, and deep expertise in the cardiovascular space, Recordati is well-equipped to broaden patient access to Amarin’s Vazkepa significantly and boost sales.
Amarin remains focused on maximizing its U.S. business, a well-established and profitable operation that continues to generate meaningful cash flows. The company also maintains a strong global presence through strategic partnerships in key international markets, such as Canada, MENA, China, Australia/New Zealand, and Southeast Asia. These collaborations, requiring minimal capital investment, allow Amarin to expand access and penetration of Vascepa/Vazkepa while supporting partners in their regulatory and commercial initiatives, driving long-term global revenue growth.
In the past 90 days, loss per share estimates for Immunocore’s 2025 have improved from $1.57 to 86 cents. Loss per share estimates for 2026 have narrowed from $1.80 to $1.33 during the same period. IMCR stock has gained 8.5% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 76.18%.
BAYRY’s 2025 earnings per share estimate has increased from $1.19 to $1.25 for 2025 over the past 90 days, while that for 2026 has gone up from $1.28 to $1.31 over the same timeframe. Year to date, shares of Bayer have surged 57.8%.
BAYRY’s earnings beat estimates in one of the trailing four quarters, matched twice and missed on the remaining occasion, the average negative surprise being 13.91%.
In the past 90 days, Agenus’ bottom-line estimates for 2025 have significantly improved from a loss of $4.66 per share to earnings of $1.56. During the same timeframe, estimates for 2026 loss per share have narrowed from $5.02 to $1.99. AGEN stock has soared 82.5% so far this year.
Agenus’ earnings beat estimates in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average negative surprise of 22.71%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU
Key Takeaways
Shares of Amarin (AMRN - Free Report) jumped 27.3% on Tuesday after the company announced that it has signed an exclusive long-term license and supply agreement with Italy-based Recordati to commercialize its sole marketed drug, Vazkepa (icosapent ethyl), across 59 countries in the EU.
AMRN’s Vazkepa is currently approved in the EU as an adjunct to diet for treating severe hypertriglyceridemia or elevated triglyceride levels and to reduce the risk of cardiovascular events (CV) in patients with persistent elevated triglycerides on statin therapy for LDL-C. The drug is also approved in the United States for the same indications as in the EU, under the brand name Vascepa.
The agreement with Recordati builds on Vazkepa’s early success in the EU, where it enjoys patent protection up to 2039, and focuses on expanding the product’s reach to patients at risk of CV, thereby boosting sales. Additionally, it will also enable Amarin to cut operational costs, thereby enhancing its financial strength.
Financial Considerations for AMRN’s Licensing Deal With Recordati
The deal grants Recordati an exclusive license to market Amarin’s Vazkepa across Europe. In return, AMRN will receive an upfront payment of $25 million, along with potential milestone payments of up to $150 million, contingent on Recordati meeting certain predefined annual net sales targets. Amarin is also entitled to receive certain supply-based revenues, including royalties related to the product’s supply under the licensing agreement.
Year to date, shares of Amarin have rallied 65.3% against the industry’s decline of 4.2%.
Image Source: Zacks Investment Research
How the Recordati Deal Benefits AMRN’s Future Growth Strategy
The partnership with Recordati further strengthens Amarin’s cash position. The deal also supports Amarin’s transition toward a leaner operating model, projected to deliver approximately $70 million in cost savings over the next 12 months, primarily from reduced commercialization expenses in the EU. This restructuring strengthens Amarin’s financial position and accelerates its path to achieving positive cash flow, while creating new revenue opportunities through supply agreements and milestone payments. As of March-end, AMRN’s balance sheet reflects nearly $300 million in cash with no debt.
Vazkepa is a strong addition to Recordati’s established cardiovascular portfolio, which accounts for around 25% of its Specialty and Primary Care business and includes treatments for conditions such as hypertension and heart failure. With operations in more than 150 countries, including a solid presence across the EU, and deep expertise in the cardiovascular space, Recordati is well-equipped to broaden patient access to Amarin’s Vazkepa significantly and boost sales.
Amarin remains focused on maximizing its U.S. business, a well-established and profitable operation that continues to generate meaningful cash flows. The company also maintains a strong global presence through strategic partnerships in key international markets, such as Canada, MENA, China, Australia/New Zealand, and Southeast Asia. These collaborations, requiring minimal capital investment, allow Amarin to expand access and penetration of Vascepa/Vazkepa while supporting partners in their regulatory and commercial initiatives, driving long-term global revenue growth.
Amarin Corporation PLC Price and Consensus
Amarin Corporation PLC price-consensus-chart | Amarin Corporation PLC Quote
AMRN’s Zacks Rank and Other Stocks to Consider
Amarin currently sports a Zacks Rank #1 (Strong Buy).
Some other top-ranked stocks in the biotech sector are Immunocore (IMCR - Free Report) , Bayer (BAYRY - Free Report) and Agenus (AGEN - Free Report) . While IMCR currently sports a Zacks Rank #1, BAYRY and AGEN carry a Zacks Rank #2 (Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 90 days, loss per share estimates for Immunocore’s 2025 have improved from $1.57 to 86 cents. Loss per share estimates for 2026 have narrowed from $1.80 to $1.33 during the same period. IMCR stock has gained 8.5% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 76.18%.
BAYRY’s 2025 earnings per share estimate has increased from $1.19 to $1.25 for 2025 over the past 90 days, while that for 2026 has gone up from $1.28 to $1.31 over the same timeframe. Year to date, shares of Bayer have surged 57.8%.
BAYRY’s earnings beat estimates in one of the trailing four quarters, matched twice and missed on the remaining occasion, the average negative surprise being 13.91%.
In the past 90 days, Agenus’ bottom-line estimates for 2025 have significantly improved from a loss of $4.66 per share to earnings of $1.56. During the same timeframe, estimates for 2026 loss per share have narrowed from $5.02 to $1.99. AGEN stock has soared 82.5% so far this year.
Agenus’ earnings beat estimates in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average negative surprise of 22.71%.